320 related articles for article (PubMed ID: 35929918)
21. Novel Platinum Nanoclusters Activate PI3K/AKT/mTOR Signaling Pathway-Mediated Autophagy for Cisplatin-Resistant Ovarian Cancer Therapy.
Zhang M; Yue H; Huang X; Wang J; Li Z; Deng X
ACS Appl Mater Interfaces; 2022 Nov; 14(43):48502-48514. PubMed ID: 36261925
[TBL] [Abstract][Full Text] [Related]
22. Theasaponin E
Li B; Tong T; Ren N; Rankin GO; Rojanasakul Y; Tu Y; Chen YC
Molecules; 2021 Mar; 26(6):. PubMed ID: 33802884
[TBL] [Abstract][Full Text] [Related]
23. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
[TBL] [Abstract][Full Text] [Related]
24. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
25. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
26. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
Santiskulvong C; Konecny GE; Fekete M; Chen KY; Karam A; Mulholland D; Eng C; Wu H; Song M; Dorigo O
Clin Cancer Res; 2011 Apr; 17(8):2373-84. PubMed ID: 21372221
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
[TBL] [Abstract][Full Text] [Related]
28. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.
Wu Q; Ma J; Wei J; Meng W; Wang Y; Shi M
Mol Oncol; 2021 Jan; 15(1):299-316. PubMed ID: 32460412
[TBL] [Abstract][Full Text] [Related]
29. Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway.
El-Kott AF; Shati AA; Al-Kahtani MA; Alqahtani S
Anal Cell Pathol (Amst); 2019; 2019():9627810. PubMed ID: 31360627
[TBL] [Abstract][Full Text] [Related]
30. Long noncoding RNA H19 promotes chemotherapy resistance in choriocarcinoma cells.
Yu S; Wu C; Tan Q; Liu H
J Cell Biochem; 2019 Sep; 120(9):15131-15144. PubMed ID: 31020694
[TBL] [Abstract][Full Text] [Related]
31. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.
Elsayed AM; Bayraktar E; Amero P; Salama SA; Abdelaziz AH; Ismail RS; Zhang X; Ivan C; Sood AK; Lopez-Berestein G; Rodriguez-Aguayo C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668685
[TBL] [Abstract][Full Text] [Related]
32. Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells
Yang H; Li H; Lu S; Shan S; Guo Y
Biomed Res Int; 2022; 2022():5739909. PubMed ID: 35281608
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
35. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
[TBL] [Abstract][Full Text] [Related]
36. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of ITGBL1 predicts poor prognosis and promotes chemoresistance in ovarian cancer.
Song J; Yang P; Lu J
Cancer Biomark; 2020; 27(1):51-61. PubMed ID: 31683459
[TBL] [Abstract][Full Text] [Related]
38. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
39. Endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance in human ovarian cancer cells.
Hu JL; Hu XL; Guo AY; Wang CJ; Wen YY; Cang SD
Oncotarget; 2017 Jul; 8(30):49380-49394. PubMed ID: 28537902
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors.
Perez-Juarez CE; Arechavaleta-Velasco F; Zeferino-Toquero M; Alvarez-Arellano L; Estrada-Moscoso I; Diaz-Cueto L
Med Oncol; 2019 Nov; 37(1):4. PubMed ID: 31713081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
